Water-soluble PDE4 inhibitors for the treatment of dry eye.
Article Details
- CitationCopy to clipboard
Govek SP, Oshiro G, Anzola JV, Beauregard C, Chen J, Coyle AR, Gamache DA, Hellberg MR, Hsien JN, Lerch JM, Liao JC, Malecha JW, Staszewski LM, Thomas DJ, Yanni JM, Noble SA, Shiau AK
Water-soluble PDE4 inhibitors for the treatment of dry eye.
Bioorg Med Chem Lett. 2010 May 1;20(9):2928-32. doi: 10.1016/j.bmcl.2010.03.023. Epub 2010 Mar 7.
- PubMed ID
- 20378348 [ View in PubMed]
- Abstract
PDE4 inhibitors have the potential to alleviate the symptoms and underlying inflammation associated with dry eye. Disclosed herein is the development of a novel series of water-soluble PDE4 inhibitors. Our studies led to the discovery of coumarin 18, which is effective in a rabbit model of dry eye and a tear secretion test in rats.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Piclamilast cAMP-specific 3',5'-cyclic phosphodiesterase 4B IC 50 (nM) 2 N/A N/A Details